The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure

[1]  S. Houser,et al.  Regulated Overexpression of the A1-Adenosine Receptor in Mice Results in Adverse but Reversible Changes in Cardiac Morphology and Function , 2006, Circulation.

[2]  J. Stasch,et al.  NO‐independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy , 2006, British journal of pharmacology.

[3]  J. Lewis,et al.  Microalbuminuria as a target to improve cardiovascular and renal outcomes. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  D. Haffner,et al.  Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3 , 2005, Journal of hypertension.

[5]  F. Villarreal,et al.  Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts. , 2004, American journal of physiology. Heart and circulatory physiology.

[6]  G. London,et al.  Cardiovascular disease in renal failure. , 2004, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[7]  M. Bak,et al.  Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  G. Gross,et al.  Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  D. Yellon,et al.  Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2A Receptor Agonist: Role of A2A Receptor and Erk1/2 , 2003, Cardiovascular Drugs and Therapy.

[10]  R. Foley,et al.  Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. , 2003, Kidney international.

[11]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[12]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[13]  W. Herzer,et al.  A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  J. Downey,et al.  AMP 579 Reduces Contracture and Limits Infarction in Rabbit Heart by Activating Adenosine A2 Receptors , 2001, Journal of cardiovascular pharmacology.

[15]  Tianxin Yang,et al.  Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Zacharia,et al.  A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts , 2001, Hypertension.

[17]  B. Hocher,et al.  ETA receptor blockade induces fibrosis of the clipped kidney in two‐kidney‐one‐clip renovascular hypertensive rats , 2000, Journal of hypertension.

[18]  J. Murray,et al.  Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. , 2000, The Journal of pharmacology and experimental therapeutics.

[19]  W. Welch,et al.  Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. , 1999, Journal of the American Society of Nephrology : JASN.

[20]  A. Bauch,et al.  Endothelin system-dependent cardiac remodeling in renovascular hypertension. , 1999, Hypertension.

[21]  E. Ritz,et al.  Cardiac remodelling in experimental renal failure--an immunohistochemical study. , 1998, Nephrology, Dialysis and Transplantation.

[22]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[23]  E. Jackson,et al.  Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. , 1998, Hypertension.

[24]  G. Grover,et al.  Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim. , 1997, The Journal of pharmacology and experimental therapeutics.

[25]  T. Saruta,et al.  Role of adenosine in the renal responses to contrast medium. , 1996, Kidney international.

[26]  B. F. Becker,et al.  Adenosine and PAF dependent mechanisms lead to myocardial reperfusion injury by neutrophils after brief ischaemia. , 1995, Cardiovascular research.

[27]  H. Kusaka,et al.  Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats. , 1995, Japanese journal of pharmacology.

[28]  N. Gretz.  The development of hypertension in the remnant kidney model after either pole resection or partial infarction of the kidney. , 1995, Journal of the American Society of Nephrology : JASN.

[29]  H. Kusaka,et al.  Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in anesthetized dogs. , 1994, Biological & pharmaceutical bulletin.

[30]  R. Berne,et al.  Protective Effects of Adenosine In Myocardial Ischemia , 1992, Circulation.

[31]  O. Carretero,et al.  Efferent arteriole tubuloglomerular feedback in the renal nephron. , 2001, Kidney international.

[32]  J. Linden.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. , 2001, Annual review of pharmacology and toxicology.

[33]  S. Zahler,et al.  [Interaction of adenosine with leukocytes and thrombocytes]. , 1996, Zeitschrift fur Kardiologie.